Upcoming

2023

Biopharmaceutical Cmo And Cro Market

Biopharmaceutical CMO and CRO Market

by Product (Biologics, Biosimilars), by Source (Mammalian, Non-Mammalian) and by Service Type (Contract Manufacturing, Contract Research): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals	Report Code: A13188	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Biopharmaceutical Cmo And Cro Market

Request Now !

Biopharmaceutical CMO and CRO Market Overview 2030

A contract manufacturing organization (CMO) is an organization that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services for new drug developments through drug manufacturing. This helps the major pharmaceutical companies to outsource those aspects of the business which allow major companies to focus on drug discovery and drug marketing.

A contract research organization (CRO) is an organization that provides support to the pharmaceutical, biotechnological, and medical device industries in the form of research services which are on contract basis. Contract research organization provide services such as biopharmaceutical development, biological assay development, commercialization, preclinical research, clinical trials, and pharmacovigilance.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the biopharmaceutical CMO and CRO market.

Top Impacting Factors

Increase in demand for novel therapeutics, rise in integration of single-use systems in production facilities, surge in incidence of chronic diseases, increase in production rate of drugs, and rise in demand for biosimilars products in market is expected to drive the growth of the market.
In addition, increase in adoption of advance healthcare information technology sector, surge in usage of outsourcing activities, rise in expenditure to build modern infrastructures, increase in R & D activities to improve technology in biopharmaceutical sector, and surge in drug discovery & drug development procedures are some factors that fuel the growth of the biopharmaceutical CMO and CRO market.
However, high cost of biopharmaceutical CMO & CRO services and data security threats restrain the growth of the biopharmaceutical CMO and CRO market.
Contrarily, rise in demand for contract research and contract manufacturing organization is expected to offer lucrative opportunities for the expansion of the market.

Market Trends

Business Expansion to Flourish the Market

In 2020, J-Star Research Inc., announced launch of new website which will help company to lead in contract research organization focused on small molecule process research and crystallization R & D.

In 2019, ANI Pharmaceuticals announced merger with WellSpring Pharma expansion of contract manufacturing organization. This expansion will help ANI pharmaceuticals to speed up drug development and drug manufacturing process

Key Benefits of the Report

This study presents the analytical depiction of biopharmaceutical CMO and CRO market industry along with the current trends and future estimations to determine the imminent investment pockets.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the biopharmaceutical CMO and CRO market share.
The current market is quantitatively analyzed to highlight the biopharmaceutical CMO and CRO market growth scenario.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Biopharmaceutical CMO and CRO Market Report

Which are the leading players active in the biopharmaceutical CMO and CRO market?
What are the current trends that will influence the market in the next few years?
What are the driving factors, restraints, and opportunities of the market?
What future projections would help in taking further strategic steps?
What is "biopharmaceutical CMO and CRO"?
What is "biopharmaceutical CMO and CRO" market prediction in the future?
Who are the leading global players in the "biopharmaceutical CMO and CRO" market?
What are the current trends and predicted trends?
What are the key benefits of the "biopharmaceutical CMO and CRO" market report?

Biopharmaceutical CMO and CRO Market Report Highlights

Aspects	Details
By Product	Biologics Biosimilars
By Source	Mammalian Non-Mammalian
By Service Type	Contract Manufacturing Contract Research
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Samsung BioLogics, ProBioGen, TOYOBO CO., LTD., Boehringer Ingelheim GmbH, JRS PHARMA, Lonza, Rentschler Biotechnologie GmbH, BIOMEVA GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Inno Biologics Sdn Bhd

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY PRODUCT
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Product
- 4.2. Biologics
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
- 4.3. Biosimilars
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
CHAPTER 5: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SOURCE
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Source
- 5.2. Mammalian
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Non-Mammalian
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
CHAPTER 6: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SERVICE TYPE
- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By Service Type
- 6.2. Contract Manufacturing
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Contract Research
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region
  - 6.3.3. Market Share Analysis, By Country
CHAPTER 7: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY REGION
- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
  - 7.2.1. Key Market Trends and Opportunities
  - 7.2.2. Market Size and Forecast, By Product
  - 7.2.3. Market Size and Forecast, By Source
  - 7.2.4. Market Size and Forecast, By Service Type
  - 7.2.5. Market Size and Forecast, By Country
  - 7.2.6. U.S. Biopharmaceutical Cmo And Cro Market
    - 7.2.6.1. Market Size and Forecast, By Product
    - 7.2.6.2. Market Size and Forecast, By Source
    - 7.2.6.3. Market Size and Forecast, By Service Type
  - 7.2.7. Canada Biopharmaceutical Cmo And Cro Market
    - 7.2.7.1. Market Size and Forecast, By Product
    - 7.2.7.2. Market Size and Forecast, By Source
    - 7.2.7.3. Market Size and Forecast, By Service Type
  - 7.2.8. Mexico Biopharmaceutical Cmo And Cro Market
    - 7.2.8.1. Market Size and Forecast, By Product
    - 7.2.8.2. Market Size and Forecast, By Source
    - 7.2.8.3. Market Size and Forecast, By Service Type
- 7.3. Europe
  - 7.3.1. Key Market Trends and Opportunities
  - 7.3.2. Market Size and Forecast, By Product
  - 7.3.3. Market Size and Forecast, By Source
  - 7.3.4. Market Size and Forecast, By Service Type
  - 7.3.5. Market Size and Forecast, By Country
  - 7.3.6. France Biopharmaceutical Cmo And Cro Market
    - 7.3.6.1. Market Size and Forecast, By Product
    - 7.3.6.2. Market Size and Forecast, By Source
    - 7.3.6.3. Market Size and Forecast, By Service Type
  - 7.3.7. Germany Biopharmaceutical Cmo And Cro Market
    - 7.3.7.1. Market Size and Forecast, By Product
    - 7.3.7.2. Market Size and Forecast, By Source
    - 7.3.7.3. Market Size and Forecast, By Service Type
  - 7.3.8. Italy Biopharmaceutical Cmo And Cro Market
    - 7.3.8.1. Market Size and Forecast, By Product
    - 7.3.8.2. Market Size and Forecast, By Source
    - 7.3.8.3. Market Size and Forecast, By Service Type
  - 7.3.9. Spain Biopharmaceutical Cmo And Cro Market
    - 7.3.9.1. Market Size and Forecast, By Product
    - 7.3.9.2. Market Size and Forecast, By Source
    - 7.3.9.3. Market Size and Forecast, By Service Type
  - 7.3.10. UK Biopharmaceutical Cmo And Cro Market
    - 7.3.10.1. Market Size and Forecast, By Product
    - 7.3.10.2. Market Size and Forecast, By Source
    - 7.3.10.3. Market Size and Forecast, By Service Type
  - 7.3.11. Russia Biopharmaceutical Cmo And Cro Market
    - 7.3.11.1. Market Size and Forecast, By Product
    - 7.3.11.2. Market Size and Forecast, By Source
    - 7.3.11.3. Market Size and Forecast, By Service Type
  - 7.3.12. Rest Of Europe Biopharmaceutical Cmo And Cro Market
    - 7.3.12.1. Market Size and Forecast, By Product
    - 7.3.12.2. Market Size and Forecast, By Source
    - 7.3.12.3. Market Size and Forecast, By Service Type
- 7.4. Asia-Pacific
  - 7.4.1. Key Market Trends and Opportunities
  - 7.4.2. Market Size and Forecast, By Product
  - 7.4.3. Market Size and Forecast, By Source
  - 7.4.4. Market Size and Forecast, By Service Type
  - 7.4.5. Market Size and Forecast, By Country
  - 7.4.6. China Biopharmaceutical Cmo And Cro Market
    - 7.4.6.1. Market Size and Forecast, By Product
    - 7.4.6.2. Market Size and Forecast, By Source
    - 7.4.6.3. Market Size and Forecast, By Service Type
  - 7.4.7. Japan Biopharmaceutical Cmo And Cro Market
    - 7.4.7.1. Market Size and Forecast, By Product
    - 7.4.7.2. Market Size and Forecast, By Source
    - 7.4.7.3. Market Size and Forecast, By Service Type
  - 7.4.8. India Biopharmaceutical Cmo And Cro Market
    - 7.4.8.1. Market Size and Forecast, By Product
    - 7.4.8.2. Market Size and Forecast, By Source
    - 7.4.8.3. Market Size and Forecast, By Service Type
  - 7.4.9. South Korea Biopharmaceutical Cmo And Cro Market
    - 7.4.9.1. Market Size and Forecast, By Product
    - 7.4.9.2. Market Size and Forecast, By Source
    - 7.4.9.3. Market Size and Forecast, By Service Type
  - 7.4.10. Australia Biopharmaceutical Cmo And Cro Market
    - 7.4.10.1. Market Size and Forecast, By Product
    - 7.4.10.2. Market Size and Forecast, By Source
    - 7.4.10.3. Market Size and Forecast, By Service Type
  - 7.4.11. Thailand Biopharmaceutical Cmo And Cro Market
    - 7.4.11.1. Market Size and Forecast, By Product
    - 7.4.11.2. Market Size and Forecast, By Source
    - 7.4.11.3. Market Size and Forecast, By Service Type
  - 7.4.12. Malaysia Biopharmaceutical Cmo And Cro Market
    - 7.4.12.1. Market Size and Forecast, By Product
    - 7.4.12.2. Market Size and Forecast, By Source
    - 7.4.12.3. Market Size and Forecast, By Service Type
  - 7.4.13. Indonesia Biopharmaceutical Cmo And Cro Market
    - 7.4.13.1. Market Size and Forecast, By Product
    - 7.4.13.2. Market Size and Forecast, By Source
    - 7.4.13.3. Market Size and Forecast, By Service Type
  - 7.4.14. Rest of Asia Pacific Biopharmaceutical Cmo And Cro Market
    - 7.4.14.1. Market Size and Forecast, By Product
    - 7.4.14.2. Market Size and Forecast, By Source
    - 7.4.14.3. Market Size and Forecast, By Service Type
- 7.5. LAMEA
  - 7.5.1. Key Market Trends and Opportunities
  - 7.5.2. Market Size and Forecast, By Product
  - 7.5.3. Market Size and Forecast, By Source
  - 7.5.4. Market Size and Forecast, By Service Type
  - 7.5.5. Market Size and Forecast, By Country
  - 7.5.6. Brazil Biopharmaceutical Cmo And Cro Market
    - 7.5.6.1. Market Size and Forecast, By Product
    - 7.5.6.2. Market Size and Forecast, By Source
    - 7.5.6.3. Market Size and Forecast, By Service Type
  - 7.5.7. South Africa Biopharmaceutical Cmo And Cro Market
    - 7.5.7.1. Market Size and Forecast, By Product
    - 7.5.7.2. Market Size and Forecast, By Source
    - 7.5.7.3. Market Size and Forecast, By Service Type
  - 7.5.8. Saudi Arabia Biopharmaceutical Cmo And Cro Market
    - 7.5.8.1. Market Size and Forecast, By Product
    - 7.5.8.2. Market Size and Forecast, By Source
    - 7.5.8.3. Market Size and Forecast, By Service Type
  - 7.5.9. UAE Biopharmaceutical Cmo And Cro Market
    - 7.5.9.1. Market Size and Forecast, By Product
    - 7.5.9.2. Market Size and Forecast, By Source
    - 7.5.9.3. Market Size and Forecast, By Service Type
  - 7.5.10. Argentina Biopharmaceutical Cmo And Cro Market
    - 7.5.10.1. Market Size and Forecast, By Product
    - 7.5.10.2. Market Size and Forecast, By Source
    - 7.5.10.3. Market Size and Forecast, By Service Type
  - 7.5.11. Rest of LAMEA Biopharmaceutical Cmo And Cro Market
    - 7.5.11.1. Market Size and Forecast, By Product
    - 7.5.11.2. Market Size and Forecast, By Source
    - 7.5.11.3. Market Size and Forecast, By Service Type
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning,2022
CHAPTER 9: COMPANY PROFILES
- 9.1. Boehringer Ingelheim GmbH
  - 9.1.1. Company Overview
  - 9.1.2. Key Executives
  - 9.1.3. Company Snapshot
  - 9.1.4. Operating Business Segments
  - 9.1.5. Product Portfolio
  - 9.1.6. Business Performance
  - 9.1.7. Key Strategic Moves and Developments
- 9.2. Lonza
  - 9.2.1. Company Overview
  - 9.2.2. Key Executives
  - 9.2.3. Company Snapshot
  - 9.2.4. Operating Business Segments
  - 9.2.5. Product Portfolio
  - 9.2.6. Business Performance
  - 9.2.7. Key Strategic Moves and Developments
- 9.3. Inno Biologics Sdn Bhd
  - 9.3.1. Company Overview
  - 9.3.2. Key Executives
  - 9.3.3. Company Snapshot
  - 9.3.4. Operating Business Segments
  - 9.3.5. Product Portfolio
  - 9.3.6. Business Performance
  - 9.3.7. Key Strategic Moves and Developments
- 9.4. Rentschler Biotechnologie GmbH
  - 9.4.1. Company Overview
  - 9.4.2. Key Executives
  - 9.4.3. Company Snapshot
  - 9.4.4. Operating Business Segments
  - 9.4.5. Product Portfolio
  - 9.4.6. Business Performance
  - 9.4.7. Key Strategic Moves and Developments
- 9.5. JRS PHARMA
  - 9.5.1. Company Overview
  - 9.5.2. Key Executives
  - 9.5.3. Company Snapshot
  - 9.5.4. Operating Business Segments
  - 9.5.5. Product Portfolio
  - 9.5.6. Business Performance
  - 9.5.7. Key Strategic Moves and Developments
- 9.6. BIOMEVA GmbH
  - 9.6.1. Company Overview
  - 9.6.2. Key Executives
  - 9.6.3. Company Snapshot
  - 9.6.4. Operating Business Segments
  - 9.6.5. Product Portfolio
  - 9.6.6. Business Performance
  - 9.6.7. Key Strategic Moves and Developments
- 9.7. ProBioGen
  - 9.7.1. Company Overview
  - 9.7.2. Key Executives
  - 9.7.3. Company Snapshot
  - 9.7.4. Operating Business Segments
  - 9.7.5. Product Portfolio
  - 9.7.6. Business Performance
  - 9.7.7. Key Strategic Moves and Developments
- 9.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  - 9.8.1. Company Overview
  - 9.8.2. Key Executives
  - 9.8.3. Company Snapshot
  - 9.8.4. Operating Business Segments
  - 9.8.5. Product Portfolio
  - 9.8.6. Business Performance
  - 9.8.7. Key Strategic Moves and Developments
- 9.9. TOYOBO CO., LTD.
  - 9.9.1. Company Overview
  - 9.9.2. Key Executives
  - 9.9.3. Company Snapshot
  - 9.9.4. Operating Business Segments
  - 9.9.5. Product Portfolio
  - 9.9.6. Business Performance
  - 9.9.7. Key Strategic Moves and Developments
- 9.10. Samsung BioLogics
  - 9.10.1. Company Overview
  - 9.10.2. Key Executives
  - 9.10.3. Company Snapshot
  - 9.10.4. Operating Business Segments
  - 9.10.5. Product Portfolio
  - 9.10.6. Business Performance
  - 9.10.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 2. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR BIOLOGICS, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR BIOSIMILARS, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SOURCE, 2022-2032 ($MILLION)
TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR MAMMALIAN, BY REGION, 2022-2032 ($MILLION)
TABLE 6. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR NON-MAMMALIAN, BY REGION, 2022-2032 ($MILLION)
TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2022-2032 ($MILLION)
TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR CONTRACT RESEARCH, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 11. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO, BY REGION, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 15. U.S. BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 16. U.S. BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 17. U.S. BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 18. CANADA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 19. CANADA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 20. CANADA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 21. MEXICO BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 22. MEXICO BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 23. MEXICO BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 24. EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY REGION, 2022-2032 ($MILLION)
TABLE 25. EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 26. EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 27. EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 28. FRANCE BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 29. FRANCE BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 30. FRANCE BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 31. GERMANY BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 32. GERMANY BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 33. GERMANY BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 34. ITALY BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 35. ITALY BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 36. ITALY BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 37. SPAIN BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 38. SPAIN BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 39. SPAIN BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 40. UK BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 41. UK BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 42. UK BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 43. RUSSIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 44. RUSSIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 45. RUSSIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY REGION, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 53. CHINA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 54. CHINA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 55. CHINA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 57. JAPAN BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 58. JAPAN BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 59. INDIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 60. INDIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 61. INDIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 62. SOUTH KOREA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 63. SOUTH KOREA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 67. AUSTRALIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 68. THAILAND BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 69. THAILAND BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 70. THAILAND BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 71. MALAYSIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 72. MALAYSIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 73. MALAYSIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 74. INDONESIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 75. INDONESIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 76. INDONESIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 77. REST OF ASIA PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 78. REST OF ASIA PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 79. REST OF ASIA PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 80. LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY REGION, 2022-2032 ($MILLION)
TABLE 81. LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 82. LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 83. LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 84. BRAZIL BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 85. BRAZIL BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 86. BRAZIL BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 87. SOUTH AFRICA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 88. SOUTH AFRICA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 89. SOUTH AFRICA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 90. SAUDI ARABIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 91. SAUDI ARABIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 92. SAUDI ARABIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 93. UAE BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 94. UAE BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 95. UAE BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 96. ARGENTINA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 97. ARGENTINA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 98. ARGENTINA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 99. REST OF LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 100. REST OF LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2022-2032 ($MILLION)
TABLE 101. REST OF LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2022-2032 ($MILLION)
TABLE 102. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
TABLE 103. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
TABLE 104. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
TABLE 105. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
TABLE 106. BOEHRINGER INGELHEIM GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107. LONZA: KEY EXECUTIVES
TABLE 108. LONZA: COMPANY SNAPSHOT
TABLE 109. LONZA: OPERATING SEGMENTS
TABLE 110. LONZA: PRODUCT PORTFOLIO
TABLE 111. LONZA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. INNO BIOLOGICS SDN BHD: KEY EXECUTIVES
TABLE 113. INNO BIOLOGICS SDN BHD: COMPANY SNAPSHOT
TABLE 114. INNO BIOLOGICS SDN BHD: OPERATING SEGMENTS
TABLE 115. INNO BIOLOGICS SDN BHD: PRODUCT PORTFOLIO
TABLE 116. INNO BIOLOGICS SDN BHD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117. RENTSCHLER BIOTECHNOLOGIE GMBH: KEY EXECUTIVES
TABLE 118. RENTSCHLER BIOTECHNOLOGIE GMBH: COMPANY SNAPSHOT
TABLE 119. RENTSCHLER BIOTECHNOLOGIE GMBH: OPERATING SEGMENTS
TABLE 120. RENTSCHLER BIOTECHNOLOGIE GMBH: PRODUCT PORTFOLIO
TABLE 121. RENTSCHLER BIOTECHNOLOGIE GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122. JRS PHARMA: KEY EXECUTIVES
TABLE 123. JRS PHARMA: COMPANY SNAPSHOT
TABLE 124. JRS PHARMA: OPERATING SEGMENTS
TABLE 125. JRS PHARMA: PRODUCT PORTFOLIO
TABLE 126. JRS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127. BIOMEVA GMBH: KEY EXECUTIVES
TABLE 128. BIOMEVA GMBH: COMPANY SNAPSHOT
TABLE 129. BIOMEVA GMBH: OPERATING SEGMENTS
TABLE 130. BIOMEVA GMBH: PRODUCT PORTFOLIO
TABLE 131. BIOMEVA GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132. PROBIOGEN: KEY EXECUTIVES
TABLE 133. PROBIOGEN: COMPANY SNAPSHOT
TABLE 134. PROBIOGEN: OPERATING SEGMENTS
TABLE 135. PROBIOGEN: PRODUCT PORTFOLIO
TABLE 136. PROBIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 137. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: KEY EXECUTIVES
TABLE 138. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: COMPANY SNAPSHOT
TABLE 139. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: OPERATING SEGMENTS
TABLE 140. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: PRODUCT PORTFOLIO
TABLE 141. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 142. TOYOBO CO., LTD.: KEY EXECUTIVES
TABLE 143. TOYOBO CO., LTD.: COMPANY SNAPSHOT
TABLE 144. TOYOBO CO., LTD.: OPERATING SEGMENTS
TABLE 145. TOYOBO CO., LTD.: PRODUCT PORTFOLIO
TABLE 146. TOYOBO CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 147. SAMSUNG BIOLOGICS: KEY EXECUTIVES
TABLE 148. SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
TABLE 149. SAMSUNG BIOLOGICS: OPERATING SEGMENTS
TABLE 150. SAMSUNG BIOLOGICS: PRODUCT PORTFOLIO
TABLE 151. SAMSUNG BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET SEGMENTATION
FIGURE 2. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET
FIGURE 3. SEGMENTATION BIOPHARMACEUTICAL CMO AND CRO MARKET
FIGURE 4. TOP INVESTMENT POCKET IN BIOPHARMACEUTICAL CMO AND CRO MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBIOPHARMACEUTICAL CMO AND CRO MARKET
FIGURE 11. BIOPHARMACEUTICAL CMO AND CRO MARKET SEGMENTATION, BY BY PRODUCT
FIGURE 12. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. BIOPHARMACEUTICAL CMO AND CRO MARKET SEGMENTATION, BY BY SOURCE
FIGURE 15. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR MAMMALIAN, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 16. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR NON-MAMMALIAN, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 17. BIOPHARMACEUTICAL CMO AND CRO MARKET SEGMENTATION, BY BY SERVICE TYPE
FIGURE 18. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 19. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR CONTRACT RESEARCH, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 24. COMPETITIVE DASHBOARD
FIGURE 25. COMPETITIVE HEATMAP: BIOPHARMACEUTICAL CMO AND CRO MARKET
FIGURE 26. Top player positioning, 2022
FIGURE 27. BOEHRINGER INGELHEIM GMBH: NET SALES, 2020-2022 ($MILLION)
FIGURE 28. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 29. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 30. LONZA: NET SALES, 2020-2022 ($MILLION)
FIGURE 31. LONZA: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 32. LONZA: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 33. INNO BIOLOGICS SDN BHD: NET SALES, 2020-2022 ($MILLION)
FIGURE 34. INNO BIOLOGICS SDN BHD: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 35. INNO BIOLOGICS SDN BHD: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 36. RENTSCHLER BIOTECHNOLOGIE GMBH: NET SALES, 2020-2022 ($MILLION)
FIGURE 37. RENTSCHLER BIOTECHNOLOGIE GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 38. RENTSCHLER BIOTECHNOLOGIE GMBH: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 39. JRS PHARMA: NET SALES, 2020-2022 ($MILLION)
FIGURE 40. JRS PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 41. JRS PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 42. BIOMEVA GMBH: NET SALES, 2020-2022 ($MILLION)
FIGURE 43. BIOMEVA GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 44. BIOMEVA GMBH: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 45. PROBIOGEN: NET SALES, 2020-2022 ($MILLION)
FIGURE 46. PROBIOGEN: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 47. PROBIOGEN: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 48. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 50. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 51. TOYOBO CO., LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 52. TOYOBO CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 53. TOYOBO CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 54. SAMSUNG BIOLOGICS: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. SAMSUNG BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 56. SAMSUNG BIOLOGICS: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Biopharmaceutical CMO and CRO Market Global Opportunity Analysis and Industry Forecast, 2023-2032

2023

Biopharmaceutical Cmo And Cro Market

Biopharmaceutical CMO and CRO Market

by Product (Biologics, Biosimilars), by Source (Mammalian, Non-Mammalian) and by Service Type (Contract Manufacturing, Contract Research): Global Opportunity Analysis and Industry Forecast, 2023-2032

COVID-19

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY PRODUCT

4.1. Market Overview

4.1.1 Market Size and Forecast, By Product

4.2. Biologics

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Biosimilars

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

CHAPTER 5: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SOURCE

5.1. Market Overview

5.1.1 Market Size and Forecast, By Source

5.2. Mammalian

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.2.2. Market Size and Forecast, By Region

5.2.3. Market Share Analysis, By Country

5.3. Non-Mammalian

5.3.1. Key Market Trends, Growth Factors and Opportunities

5.3.2. Market Size and Forecast, By Region

5.3.3. Market Share Analysis, By Country

CHAPTER 6: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SERVICE TYPE

6.1. Market Overview

6.1.1 Market Size and Forecast, By Service Type

6.2. Contract Manufacturing

6.2.1. Key Market Trends, Growth Factors and Opportunities

6.2.2. Market Size and Forecast, By Region

6.2.3. Market Share Analysis, By Country

6.3. Contract Research

6.3.1. Key Market Trends, Growth Factors and Opportunities

6.3.2. Market Size and Forecast, By Region

6.3.3. Market Share Analysis, By Country

CHAPTER 7: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY REGION

7.1. Market Overview

7.1.1 Market Size and Forecast, By Region

7.2. North America

7.2.1. Key Market Trends and Opportunities

7.2.2. Market Size and Forecast, By Product

7.2.3. Market Size and Forecast, By Source

7.2.4. Market Size and Forecast, By Service Type

7.2.5. Market Size and Forecast, By Country

7.2.6. U.S. Biopharmaceutical Cmo And Cro Market

7.2.6.1. Market Size and Forecast, By Product

7.2.6.2. Market Size and Forecast, By Source

7.2.6.3. Market Size and Forecast, By Service Type

Biopharmaceutical CMO and CRO Market
Global Opportunity Analysis and Industry Forecast, 2023-2032